GERON CORP (1GERN.MI) Stock Price, Forecast & Analysis
Europe - BIT:1GERN - US3741631036 - Common Stock
1GERN.MI Key Statistics, Chart & Performance
The current stock price of 1GERN.MI is 0.971 EUR.
1GERN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.74 | 44.96B | ||
| 1AE.DE | ARGENX SE | 67.72 | 44.95B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.96B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 820.63M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 517.80M | ||
| FYB.DE | FORMYCON AG | N/A | 341.03M | ||
| VLA.PA | VALNEVA SE | N/A | 314.28M |
Related stock screener links
About 1GERN.MI
Company Profile
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Company Info
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA US
Employees: 229
Phone: 16504737700
GERON CORP / 1GERN.MI FAQ
Can you describe the business of GERON CORP?
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
What is the current price of 1GERN stock?
The current stock price of 1GERN.MI is 0.971 EUR. The price decreased by -13.38% in the last trading session.
What is the dividend status of GERON CORP?
1GERN.MI does not pay a dividend.
What is the ChartMill rating of GERON CORP stock?
1GERN.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about GERON CORP (1GERN.MI) stock?
15 analysts have analysed 1GERN.MI and the average price target is 3.03 EUR. This implies a price increase of 211.78% is expected in the next year compared to the current price of 0.971.
When does GERON CORP (1GERN.MI) report earnings?
GERON CORP (1GERN.MI) will report earnings on 2026-02-24, after the market close.
1GERN.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1GERN.MI.
1GERN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1GERN.MI. While 1GERN.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
1GERN.MI Financial Highlights
Over the last trailing twelve months 1GERN.MI reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 63.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.85% | ||
| ROE | -33.91% | ||
| Debt/Equity | 0.46 |
1GERN.MI Forecast & Estimates
15 analysts have analysed 1GERN.MI and the average price target is 3.03 EUR. This implies a price increase of 211.78% is expected in the next year compared to the current price of 0.971.
For the next year, analysts expect an EPS growth of 57.92% and a revenue growth 179.18% for 1GERN.MI